Skip to main
ARDT

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Ardent Health Inc demonstrated strong financial performance with an EBITDA of $143 million, reflecting a significant year-over-year increase of 46% and an improved margin of 9.1%, up 240 basis points. The company's admissions growth of 2.9% positioned it at the high end of its annual projection, reinforcing its operational stability, while improvements in contract labor to 3.5% of salaries and wages indicate effective cost management. Additionally, positive trends within the hospital sector, alongside the company’s strategic focus on enhancing outpatient services, suggest considerable growth opportunities that indicate Ardent is positioned to better realize its earning potential.

Bears say

Ardent Health Inc. has reported an EBITDA of $143 million for the quarter, representing a 46% year-over-year increase, yet it fell 2% short of the anticipated $146 million due to a notable contribution of $15 million to $20 million from Kansas SDPs. The company's revenue adjustments of $43 million related to its shift to the Kodiak revenue cycle management platform have led to a more conservative outlook on accounts receivable collectability, further exacerbating concerns over growth prospects. Consequently, revised EBITDA-NCI estimates for 2025 and 2026 have been lowered to $542 million and $536 million, respectively, reflecting anticipated challenges in revenue generation and a reduced growth trajectory.

ARDT has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 12 analysts, ARDT has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.